![](/img/cover-not-exists.png)
A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone
Attard, G., Montgomery, R., Vaishampayan, U., Gordon, M., Smith, D., Antonarakis, E., Rudsinski, E., Perabo, F., Chi, K., Fizazi, K.Volume:
15
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/s1569-9056(16)30439-0
Date:
December, 2016
File:
PDF, 216 KB
english, 2016